The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers

The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease

(2021) Joel Simrén et al.   Alzheimers & Dementia

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology

(2021) Nicholas J. Ashton et al.   ACTA NEUROPATHOLOGICA

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework

(2021) A. Leuzy et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update

(2021) Marina Boccardi et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer’s Disease Multimodal Biomarker Discovery Cohort

(2020) Sarah Westwood et al.   JOURNAL OF ALZHEIMERS DISEASE

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

(2020) Shorena Janelidze et al.   NATURE MEDICINE

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

(2020) Elisabeth H. Thijssen et al.   NATURE MEDICINE

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

(2020) Thomas K Karikari et al.   LANCET NEUROLOGY

Nanoparticle-based immunomagnetic assay of plasma biomarkers for differentiating dementia and prodromal states of Alzheimer's disease – A cross-validation study

(2020) Ming-Jang Chiu et al.   Nanomedicine-Nanotechnology Biology and Medicine

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

(2020) Nicolas R. Barthélemy et al.   NATURE MEDICINE

An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders

(2020) Nicholas J. Ashton et al.   Nature Reviews Neurology

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease

(2020) Shorena Janelidze et al.   Nature Communications

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification

(2020) Nicolas R. Barthélemy et al.   Alzheimers Research & Therapy

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease

(2020) Niklas Mattsson-Carlgren et al.   Science Advances

Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline

(2020) Juan Lantero Rodriguez et al.   ACTA NEUROPATHOLOGICA

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

(2020) Sebastian Palmqvist et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease

(2020) Nicolas R. Barthélemy et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration

(2020) Alberto Benussi et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study

(2020) Antoinette O’Connor et al.   MOLECULAR PSYCHIATRY

Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19

(2020) Nelly Kanberg et al.   NEUROLOGY

Sex differences in CSF biomarkers vary by Alzheimer’s disease stage and APOE ε4 genotype

(2020) Rosha Babapour Mofrad et al.   NEUROLOGY

Remote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population Study

(2020) Kumar B. Rajan et al.   ANNALS OF NEUROLOGY

Plasma NT1 Tau is a Specific and Early Marker of Alzheimer's Disease

(2020) David Mengel et al.   ANNALS OF NEUROLOGY

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease

(2020) Niklas Mattsson-Carlgren et al.   BRAIN

Sex-dependent effect of APOE on Alzheimer's disease and other age-related neurodegenerative disorders

(2020) Julia Gamache et al.   Disease Models & Mechanisms

Neurofilament light as an outcome predictor after cardiac arrest: a post hoc analysis of the COMACARE trial

(2020) Lauri Wihersaari et al.   INTENSIVE CARE MEDICINE

Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration

(2020) Alberto Benussi et al.   JOURNAL OF ALZHEIMERS DISEASE

Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative

(2020) Thomas K. Karikari et al.   MOLECULAR PSYCHIATRY

Evaluation of a novel immunoassay to detect p-Tau Thr127 in the CSF to distinguish Alzheimer disease from other dementias

(2020) Jozef Hanes et al.   NEUROLOGY

Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology

(2020) Inge M. W. Verberk et al.   Alzheimers Research & Therapy

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis

(2020) Thomas K. Karikari et al.   Alzheimers & Dementia

Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration

(2019) Nicholas J. Ashton et al.   Acta Neuropathologica Communications

A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease

(2019) Nicholas J. Ashton et al.   Science Advances

Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes

(2019) Matthew P. Pase et al.   JAMA Neurology

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease

(2019) Carla M. Startin et al.   Alzheimers Research & Therapy

Subtyping of circulating exosome-bound amyloid β reflects brain plaque deposition

(2019) Carine Z. J. Lim et al.   Nature Communications

Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid

(2019) Valeria Lifke et al.   CLINICAL BIOCHEMISTRY

Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease

(2019) Niklas Mattsson et al.   JAMA Neurology

Towards a unified protocol for handling of CSF before β-amyloid measurements

(2019) Shorena Janelidze et al.   Alzheimers Research & Therapy

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status

(2019) Sebastian Palmqvist et al.   JAMA Neurology

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

(2019) Sebastian Palmqvist et al.   EMBO Molecular Medicine

Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer’s disease

(2019) Maria João Leitão et al.   Alzheimers Research & Therapy

Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography

(2018) Michelle M. Mielke et al.   Alzheimers & Dementia

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

Update on biomarkers for amyloid pathology in Alzheimer's disease

(2018) Nicholas J Ashton et al.   Biomarkers in Medicine

Burden of high blood pressure as a contributing factor to stroke in the Japanese community-based diabetic population

(2018) Ryosuke Komi et al.   HYPERTENSION RESEARCH

A Decade of Blood Biomarkers for Alzheimer’s Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication

(2018) Liu Shi et al.   JOURNAL OF ALZHEIMERS DISEASE

Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer’s Disease

(2018) Che-Chuan Yang et al.   JOURNAL OF ALZHEIMERS DISEASE

High performance plasma amyloid-β biomarkers for Alzheimer’s disease

(2018) Akinori Nakamura et al.   NATURE

No association of salivary total tau concentration with Alzheimer's disease

(2018) Nicholas J. Ashton et al.   NEUROBIOLOGY OF AGING

Tau Kinetics in Neurons and the Human Central Nervous System

(2018) Chihiro Sato et al.   NEURON

High salt intake increases plasma trimethylamine N-oxide (TMAO) concentration and produces gut dysbiosis in rats

(2018) Klaudia Bielinska et al.   NUTRITION

Plasma Biomarkers Differentiate Parkinson’s Disease From Atypical Parkinsonism Syndromes

(2018) Chin-Hsien Lin et al.   Frontiers in Aging Neuroscience

Association of Changes in Plasma Neurofilament Light and Tau Levels With Anesthesia and Surgery

(2018) Lisbeth Evered et al.   JAMA Neurology

Plasma amyloid as pre-screener for the earliest Alzheimer's pathological changes

(2018) Inge M.W. Verberk et al.   ANNALS OF NEUROLOGY

Meta-Analysis of Plasma Amyloid-β levels in Alzheimer's Disease

(2018) Fei Song et al.   JOURNAL OF ALZHEIMERS DISEASE

Biomarkers for Alzheimer's disease: current status and prospects for the future

(2018) K. Blennow et al.   JOURNAL OF INTERNAL MEDICINE

Aging and APOE-ε4 are determinative factors of plasma Aβ 42 levels

(2018) Takumi Nakamura et al.   Annals of Clinical and Translational Neurology

Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease

(2018) Claudia Cicognola et al.   ACTA NEUROPATHOLOGICA

Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease

(2018) Zhicheng Chen et al.   Alzheimers & Dementia

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result

(2018) Sarah Westwood et al.   Frontiers in Aging Neuroscience

Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome

(2017) Harutsugu Tatebe et al.   Molecular Neurodegeneration

Cryo-EM structures of tau filaments from Alzheimer’s disease

(2017) Anthony W. P. Fitzpatrick et al.   NATURE

The biomarker-based diagnosis of Alzheimer's disease. 2—lessons from oncology

(2017) Marina Boccardi et al.   NEUROBIOLOGY OF AGING

Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

(2017) Valentina Garibotto et al.   NEUROBIOLOGY OF AGING

Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap

(2017) Giovanni B. Frisoni et al.   NEUROBIOLOGY OF AGING

Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

(2017) Konstantinos Chiotis et al.   NEUROBIOLOGY OF AGING

Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

(2017) Chiara Cerami et al.   NEUROBIOLOGY OF AGING

Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

(2017) Mara ten Kate et al.   NEUROBIOLOGY OF AGING

Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease

(2017) Joana B. Pereira et al.   NEUROBIOLOGY OF AGING

Clinical validity of presynaptic dopaminergic imaging with  123 I-ioflupane and noradrenergic imaging with 123 I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework

(2017) Ida Sonni et al.   NEUROBIOLOGY OF AGING

Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

(2017) Niklas Mattsson et al.   NEUROBIOLOGY OF AGING

Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample

(2017) Renaud La Joie et al.   NEUROLOGY

Blood-based NfL

(2017) Oskar Hansson et al.   NEUROLOGY

Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients

(2017) Anne-Brita Knapskog et al.   BMC Geriatrics

Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment

(2017) Shorena Janelidze et al.   JAMA Neurology

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease

(2017) Niklas Mattsson et al.   JAMA Neurology

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

(2016) Bob Olsson et al.   LANCET NEUROLOGY

Plasma tau in Alzheimer disease

(2016) Niklas Mattsson et al.   NEUROLOGY

Plasma β-amyloid in Alzheimer’s disease and vascular disease

(2016) Shorena Janelidze et al.   Scientific Reports

Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research

(2015) Sid E. O'Bryant et al.   Alzheimers & Dementia

Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis

(2015) Hanne Struyfs et al.   Frontiers in Neurology

Plasma Aβ but Not Tau is Related to Brain PiB Retention in Early Alzheimer’s Disease

(2014) Kai-Yuan Tzen et al.   ACS Chemical Neuroscience

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

Plasma phospholipids identify antecedent memory impairment in older adults

(2014) Mark Mapstone et al.   NATURE MEDICINE

The amyloid-β degradation pattern in plasma—A possible tool for clinical trials in Alzheimer's disease

(2014) Josef Pannee et al.   NEUROSCIENCE LETTERS

Novel plasma biomarker surrogating cerebral amyloid deposition

(2014) Naoki KANEKO et al.   PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

Blood Biomarkers for Brain Injury in Concussed Professional Ice Hockey Players

(2014) Pashtun Shahim et al.   JAMA Neurology

Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI

(2013) Jon B. Toledo et al.   ACTA NEUROPATHOLOGICA

Plasma tau levels in Alzheimer's disease

(2013) Henrik Zetterberg et al.   Alzheimers Research & Therapy

Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010

(2012) Thomas G. Beach et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: Results of a pilot study

(2012) Jeffrey Randall et al.   RESUSCITATION

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

Amyloid Precursor Protein Processing and Alzheimer's Disease

(2011) Richard J. O'Brien et al.   Annual Review of Neuroscience

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

(2011) Christopher M. Clark   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Hypoxia Due to Cardiac Arrest Induces a Time-Dependent Increase in Serum Amyloid β Levels in Humans

(2011) Henrik Zetterberg et al.   PLoS One

Accumulation of Aspartic Acid421- and Glutamic Acid391-Cleaved Tau in Neurofibrillary Tangles Correlates With Progression in Alzheimer Disease

(2009) Gustavo Basurto-Islas et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment

(2008) Clifford R. Jack et al.   BRAIN

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

(2008) Milos D. Ikonomovic et al.   BRAIN

Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment

(2008) Oskar Hansson et al.   NEUROBIOLOGY OF AGING